Coya Therapeutics

COYA

Market cap $90.5M

Overview Fund Activity

5.41 USD

-0.26

4.59%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

5.40

-0.01

0.18%

1 day

-4.59%

5 days

-14.94%

1 month

-9.98%

3 months

1.69%

6 months

-21.02%

Year to date

-5.25%

1 year

-11.89%

5 years

18.38%

10 years

18.38%

About: Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Employees: 8

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

27% more funds holding

Funds holding: 26 [Q1] → 33 (+7) [Q2]

1.04% less ownership

Funds ownership: 27.87% [Q1] → 26.83% (-1.04%) [Q2]

14% less capital invested

Capital invested by funds: $30.2M [Q1] → $25.8M (-$4.37M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

159% upside

Avg. target

$16.5

205% upside

High target

$18

233% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital Jason Kolbert	$18	Buy Maintained	17 Sep 2025
Chardan Capital Keay Nakae	$14	Buy Maintained	17 Sep 2025
HC Wainwright & Co. Raghuram Selvaraju	$18	Buy Reiterated	27 Aug 2025
Lake Street Chad Messer	$16	Buy Initiated	9 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about COYA published over the past 30 days

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by chronic and sustained inflammation; COYA 303 demonstrated significant attenuation of neuroinflammation in cortex and hippocampus brain regions and upregulation of anti-inflammatory markers, and significant improvement of systemic Treg function and pro-inflammatory cytokines; Results from the first cohort of this in-vivo animal study confirm the previously reported positive findings from in vitro human immune cell systems demonstrating that COYA 303 significantly enhances Treg suppressive function and survival in highly inflammatory microenvironments. HOUSTON , Sept.

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS; Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025; The COYA 302 study will be presented during the NEALS Educational Webinar on September 29, 2025. HOUSTON , Sept.

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Arun Swaminathan, Chief Executive Officer of Coya Therapeutics, Inc. (“Coya” or the “Company”) (NASDAQ: COYA), a clinical-stage biotechnology company developing Treg-modulating therapies to address ALS and other neurodegenerative diseases.

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

HOUSTON , Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming investor conferences this month.

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Zacks Investment Research

Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?

Coya Therapeutics, Inc. (COYA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, COYA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON , Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration ("FDA" or the "Agency") has accepted its Investigational New Drug (IND) application for COYA 302. This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zacks Investment Research

Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates

Coya Therapeutics, Inc. (COYA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.

Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

HOUSTON , Aug. 12, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended June 30, 2025. Recent Corporate Highlights Submitted to FDA on June 30, 2025, additional nonclinical data to support the start of the COYA 302 Phase 2 trial in patients with ALS Published results of scientific research linking inflammation and oxidative stress to the progression of Parkinson's Disease (PD).

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Zacks Investment Research

Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?

Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the publication of a new research study, partially funded by Coya. The study, led by Drs. Aaron Thome, a scientific advisor to Coya, and Stanley H. Appel, the chairperson of Coya's Scientific Advisory Board, explores the role of immu.

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

See News Rankings

Charts implemented using Lightweight Charts™